JP2002517451A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002517451A5 JP2002517451A5 JP2000553084A JP2000553084A JP2002517451A5 JP 2002517451 A5 JP2002517451 A5 JP 2002517451A5 JP 2000553084 A JP2000553084 A JP 2000553084A JP 2000553084 A JP2000553084 A JP 2000553084A JP 2002517451 A5 JP2002517451 A5 JP 2002517451A5
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98110433.4 | 1998-06-08 | ||
| EP98110433 | 1998-06-08 | ||
| PCT/EP1999/003746 WO1999064016A1 (en) | 1998-06-08 | 1999-05-29 | Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006025756A Division JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＦＮ−アルファ及びリバビリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002517451A JP2002517451A (ja) | 2002-06-18 |
| JP2002517451A5 true JP2002517451A5 (ja) | 2005-12-22 |
| JP3839667B2 JP3839667B2 (ja) | 2006-11-01 |
Family
ID=8232086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000553084A Expired - Lifetime JP3839667B2 (ja) | 1998-06-08 | 1999-05-29 | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| JP2006025756A Pending JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＦＮ−アルファ及びリバビリンの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006025756A Pending JP2006160759A (ja) | 1998-06-08 | 2006-02-02 | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＦＮ−アルファ及びリバビリンの使用 |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US20030053986A1 (ja) |
| EP (1) | EP1087778B1 (ja) |
| JP (2) | JP3839667B2 (ja) |
| KR (2) | KR20050055053A (ja) |
| CN (1) | CN1170543C (ja) |
| AR (1) | AR019855A1 (ja) |
| AT (1) | ATE307597T1 (ja) |
| AU (1) | AU767131B2 (ja) |
| BR (1) | BR9911076A (ja) |
| CA (1) | CA2334267C (ja) |
| CL (1) | CL2010000828A1 (ja) |
| CO (1) | CO5050297A1 (ja) |
| CZ (1) | CZ298681B6 (ja) |
| DE (1) | DE69927971T2 (ja) |
| DK (1) | DK1087778T3 (ja) |
| ES (1) | ES2251196T3 (ja) |
| HK (1) | HK1037981A1 (ja) |
| HR (1) | HRP20000808A2 (ja) |
| HU (1) | HU228218B1 (ja) |
| ID (1) | ID29285A (ja) |
| IL (2) | IL139786A0 (ja) |
| MA (1) | MA26641A1 (ja) |
| MY (1) | MY124091A (ja) |
| NO (1) | NO325598B1 (ja) |
| NZ (1) | NZ508249A (ja) |
| PE (1) | PE20000560A1 (ja) |
| PL (1) | PL192364B1 (ja) |
| RS (1) | RS50144B (ja) |
| RU (1) | RU2271217C2 (ja) |
| SA (1) | SA99200208B1 (ja) |
| SI (1) | SI1087778T1 (ja) |
| TR (1) | TR200003635T2 (ja) |
| TW (1) | TWI241913B (ja) |
| WO (1) | WO1999064016A1 (ja) |
| ZA (1) | ZA200006814B (ja) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ508249A (en) * | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| NZ547204A (en) | 2000-05-26 | 2008-01-31 | Idenix Cayman Ltd | Methods and compositions for treating flaviviruses and pestiviruses |
| WO2002011749A1 (en) * | 2000-08-07 | 2002-02-14 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis c with thymosin, interferon and ribavirin |
| US7208167B2 (en) | 2000-08-07 | 2007-04-24 | Sciclone Pharmaceuticals, Inc. | Treatment of hepatitis C with thymosin and peptide combination therapy |
| US7179791B2 (en) | 2001-01-11 | 2007-02-20 | Duke University | Inhibiting GS-FDH to modulate NO bioactivity |
| KR100480429B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체 |
| KR20050035194A (ko) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘 |
| MXPA04012709A (es) | 2002-06-28 | 2005-09-30 | Idenix Cayman Ltd | Profarmacos modificados de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
| NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation |
| ES2470771T3 (es) * | 2002-12-12 | 2014-06-24 | Idenix Pharmaceuticals, Inc | Procedimiento para la producción de nucle�sidos ramificados en 2' |
| RU2005123395A (ru) * | 2002-12-23 | 2006-01-27 | Айденикс (Кайман) Лимитед (Ky) | Способ получения 3-нуклеозидных пролекарств |
| EP2345661A1 (en) | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modified fluorinated nucleoside analogues |
| WO2006000922A2 (en) * | 2004-06-23 | 2006-01-05 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| US8886272B2 (en) | 2004-07-13 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| EP1809301B1 (en) | 2004-09-14 | 2019-11-06 | Gilead Pharmasset LLC | 2-fluoro-2-alkyl-substituted d-ribonolactone intermediates |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| CN101242857A (zh) * | 2005-08-15 | 2008-08-13 | 弗·哈夫曼-拉罗切有限公司 | 用于HBV治疗的PEG-IFNa和利巴韦林 |
| US9201979B2 (en) * | 2005-09-14 | 2015-12-01 | Millennial Media, Inc. | Syndication of a behavioral profile associated with an availability condition using a monetization platform |
| CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
| EP2313430B1 (en) | 2008-06-24 | 2018-05-02 | Technische Universität München | Muteins of hngal and related proteins with affinity for a given target |
| PE20110343A1 (es) * | 2008-09-17 | 2011-06-25 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina |
| EA019341B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Фосфорамидаты нуклеозидов |
| PA8855701A1 (es) | 2008-12-23 | 2010-07-27 | Análogos de nucleósidos | |
| EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
| JP2012526149A (ja) | 2009-05-08 | 2012-10-25 | サイクローン・ファーマシューティカルズ・インコーポレイテッド | ワクチン増強剤としてのαチモシンペプチド |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| EP2550958B1 (en) | 2009-08-05 | 2018-10-10 | Pieris Pharmaceuticals GmbH | Controlled release formulations of lipocalin muteins |
| US8822496B2 (en) | 2009-10-30 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Dosage regimens for HCV combination therapy |
| KR101842076B1 (ko) | 2009-12-07 | 2018-03-27 | 피어이스 파마슈티컬즈 게엠베하 | 주어진 표적에 대한 친화성을 갖는 인간의 리포칼린 2의 뮤테인 |
| AU2011235044A1 (en) | 2010-03-31 | 2012-11-22 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| CN103038249B (zh) | 2010-06-08 | 2016-04-13 | 皮里斯股份公司 | 结合IL-4受体α的泪脂质运载蛋白突变蛋白 |
| SG10201505785QA (en) | 2010-08-16 | 2015-09-29 | Pieris Ag | Binding proteins for hepcidin |
| EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| EP3042910B1 (en) | 2010-11-30 | 2019-01-09 | Gilead Pharmasset LLC | 2'-spiro-nucleosides for use in the therapy of hepatitis c |
| US9221885B2 (en) | 2010-12-02 | 2015-12-29 | Pieris Ag | Muteins of human lipocalin 2 with affinity for CTLA-4 |
| WO2013040492A2 (en) | 2011-09-16 | 2013-03-21 | Gilead Sciences, Inc. | Methods for treating hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| HUE042720T2 (hu) | 2011-12-13 | 2019-07-29 | Pieris Pharmaceuticals Gmbh | Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140039923A1 (en) * | 2012-08-03 | 2014-02-06 | AxelaCare Health Solutions, Inc. | Computer program, method, and system for receiving and managing patient data gathered during patient treatments |
| WO2014076321A1 (en) | 2012-11-19 | 2014-05-22 | Pieris Ag | Novel specific-binding polypeptides and uses thereof |
| KR20140119012A (ko) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| WO2014140210A1 (en) | 2013-03-14 | 2014-09-18 | Pieris Ag | Novel binding proteins for pcsk9 |
| JP2016529293A (ja) | 2013-08-27 | 2016-09-23 | ギリアド ファーマセット エルエルシー | ２つの抗ウイルス化合物の組合せ製剤 |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| SG10201912019WA (en) | 2014-05-22 | 2020-02-27 | Pieris Pharmaceuticals Gmbh | Novel specific-binding polypeptides and uses thereof |
| KR20170105609A (ko) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | 신생혈관형성에 특이적인 신규한 단백질 |
| SG11201706621SA (en) | 2015-02-18 | 2017-09-28 | Sanofi Sa | Novel proteins specific for pyoverdine and pyochelin |
| MX2017014082A (es) | 2015-05-04 | 2018-06-28 | Pieris Pharmaceuticals Gmbh | Nuevas proteinas especificas para cd137. |
| RU2727165C2 (ru) | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| WO2016184882A1 (en) | 2015-05-18 | 2016-11-24 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| EA201890198A1 (ru) | 2015-07-15 | 2018-07-31 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Новые белки, специфичные в отношении lag-3 |
| BR112018010887A2 (pt) | 2015-11-30 | 2018-11-21 | Pieris Australia Pty Ltd | polipeptídeo de fusão |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| AU2018209178B2 (en) | 2017-01-18 | 2021-07-29 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for LAG-3 |
| PL3830120T3 (pl) | 2018-07-31 | 2023-10-09 | Pieris Pharmaceuticals Gmbh | NOWE BIAŁKO FUZYJNE SWOISTE WOBEC CD137 i PD-L1 |
| US20220153864A1 (en) | 2019-02-26 | 2022-05-19 | Pieris Pharmaceuticals Gmbh | Novel Fusion Proteins Specific for CD137 and GPC3 |
| JP2023527908A (ja) | 2020-06-05 | 2023-06-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | ４－１ｂｂをターゲティングする多量体免疫調節物質 |
| WO2022214649A1 (en) | 2021-04-08 | 2022-10-13 | Pieris Pharmaceuticals Gmbh | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
| US4681848A (en) * | 1982-09-22 | 1987-07-21 | Takeda Chemical Industries, Ltd. | Novel peptide and use thereof |
| GB8430252D0 (en) * | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DE3719046A1 (de) * | 1987-06-06 | 1988-12-15 | Basf Ag | Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5238915A (en) * | 1991-02-08 | 1993-08-24 | Wakunaga Seiyaku K.K. | Aromatic composition and method for controlling aroma |
| US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| HUT75533A (en) * | 1993-11-10 | 1997-05-28 | Schering Corp | Improved interferon polymer conjugates |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| US5695760A (en) * | 1995-04-24 | 1997-12-09 | Boehringer Inglehiem Pharmaceuticals, Inc. | Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation |
| US6387365B1 (en) * | 1995-05-19 | 2002-05-14 | Schering Corporation | Combination therapy for chronic hepatitis C infection |
| US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| PT858343E (pt) * | 1995-11-02 | 2004-07-30 | Schering Corp | Terapia por infusao continua de uma dose baixa de citoquina |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| NZ508249A (en) * | 1998-06-08 | 2003-02-28 | F | Use of PEG-IFN-alpha conjugates in association with ribavirin for the treatment of chronic hepatitis C |
-
1999
- 1999-05-29 NZ NZ508249A patent/NZ508249A/xx not_active IP Right Cessation
- 1999-05-29 RU RU2003119460/14A patent/RU2271217C2/ru active
- 1999-05-29 ES ES99927804T patent/ES2251196T3/es not_active Expired - Lifetime
- 1999-05-29 EP EP99927804A patent/EP1087778B1/en not_active Expired - Lifetime
- 1999-05-29 ID IDW20002551A patent/ID29285A/id unknown
- 1999-05-29 CZ CZ20004487A patent/CZ298681B6/cs not_active IP Right Cessation
- 1999-05-29 CA CA002334267A patent/CA2334267C/en not_active Expired - Lifetime
- 1999-05-29 SI SI9930843T patent/SI1087778T1/sl unknown
- 1999-05-29 JP JP2000553084A patent/JP3839667B2/ja not_active Expired - Lifetime
- 1999-05-29 KR KR1020057009098A patent/KR20050055053A/ko not_active Application Discontinuation
- 1999-05-29 DK DK99927804T patent/DK1087778T3/da active
- 1999-05-29 BR BR9911076-8A patent/BR9911076A/pt not_active Application Discontinuation
- 1999-05-29 RS YUP-770/00A patent/RS50144B/sr unknown
- 1999-05-29 IL IL13978699A patent/IL139786A0/xx active IP Right Grant
- 1999-05-29 KR KR1020007013843A patent/KR20010052622A/ko active Search and Examination
- 1999-05-29 TR TR2000/03635T patent/TR200003635T2/xx unknown
- 1999-05-29 PL PL344794A patent/PL192364B1/pl unknown
- 1999-05-29 HU HU0102033A patent/HU228218B1/hu unknown
- 1999-05-29 AT AT99927804T patent/ATE307597T1/de active
- 1999-05-29 CN CNB998071706A patent/CN1170543C/zh not_active Expired - Lifetime
- 1999-05-29 AU AU45033/99A patent/AU767131B2/en not_active Expired
- 1999-05-29 WO PCT/EP1999/003746 patent/WO1999064016A1/en active IP Right Grant
- 1999-05-29 DE DE69927971T patent/DE69927971T2/de not_active Expired - Lifetime
- 1999-06-02 SA SA99200208A patent/SA99200208B1/ar unknown
- 1999-06-04 CO CO99035303A patent/CO5050297A1/es unknown
- 1999-06-04 TW TW088109246A patent/TWI241913B/zh not_active IP Right Cessation
- 1999-06-04 AR ARP990102664A patent/AR019855A1/es not_active Application Discontinuation
- 1999-06-04 PE PE1999000478A patent/PE20000560A1/es not_active Application Discontinuation
- 1999-06-07 MY MYPI99002297A patent/MY124091A/en unknown
- 1999-06-08 MA MA25613A patent/MA26641A1/fr unknown
-
2000
- 2000-11-20 IL IL139786A patent/IL139786A/en not_active IP Right Cessation
- 2000-11-21 ZA ZA200006814A patent/ZA200006814B/en unknown
- 2000-11-24 HR HR20000808A patent/HRP20000808A2/hr not_active Application Discontinuation
- 2000-12-05 NO NO20006178A patent/NO325598B1/no not_active IP Right Cessation
-
2001
- 2001-11-07 US US10/037,064 patent/US20030053986A1/en not_active Abandoned
- 2001-12-20 HK HK01108946A patent/HK1037981A1/xx not_active IP Right Cessation
-
2004
- 2004-07-26 US US10/899,726 patent/US20050031589A1/en not_active Abandoned
-
2006
- 2006-02-02 JP JP2006025756A patent/JP2006160759A/ja active Pending
-
2007
- 2007-01-24 US US11/657,287 patent/US20070196385A1/en not_active Abandoned
-
2010
- 2010-08-04 CL CL2010000828A patent/CL2010000828A1/es unknown